On November 30, CEO Martin Vidaeus from Redwood Pharma will present at Aktiespararnas Stora Aktiedagen Digitalt (www.aktiespararna.se/aktiviteter/evenemang) in Stockholm. The presentation will be in English. The program and registration for the event can be found on the event’s website, where a link to the live streamed broadcast of the presentation will also be available on November 30.

The company will present:

• An update of the company’s operations and milestones
• An update of RP101 and its development
• An introduction to the new RP501 dry eye program
• Plans for the coming 12 months

For more information:
Martin Vidaeus, CEO Redwood Pharma AB (publ.)
Tel: +46 (0) 70 232 29 29
E-mail: martin.vidaeus@redwoodpharma.com

About Redwood Pharma
Redwood Pharma develops ophthalmic products for unmet medical needs through novel approaches. In providing commercial partners and their customers with effective medical solutions, the company currently has products in development to treat dry eye disease in different target patient populations. The RP101 program targets moderate-to-severe dry eye disease in postmenopausal women by delivering a low-dose estrogen therapy to the front of the eye. The RP501 program aims to treat milder forms of dry eye in a broader patient population including both men and women.  For other potential drug substances and therapeutic areas, the Company can employ the IntelliGel drug delivery platform that enhances patient convenience by controlling dosing and potentially reducing the number of instillations per day and subsequent side-effects. Redwood Pharma leverages its strengths in early clinical development and aims to generate revenues through, among others, licensing agreements with companies that have capabilities to manufacture and sell medical products worldwide.

Redwood Pharma AB (publ) is listed on the Spotlight Stock Market (Ticker: REDW.ST, ISIN: SE008294789).